Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
23 studies found for:    2502
Show Display Options
Rank Status Study
1 Completed Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients
Condition: Chagas Disease
Intervention: Drug: Nifurtimox (BAYa2502)
2 Recruiting Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease
Condition: Chagas Disease
Interventions: Drug: Nifurtimox (BAYA2502);   Drug: Nifurtimox (BAYA2502) followed by Placebo
3 Active, not recruiting Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Carboplatin;   Biological: Rituximab;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis
4 Completed Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
Condition: Chagas Disease
Interventions: Drug: Nifurtimox (BAYa2502) (4 x 30 mg tablet);   Drug: Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);   Drug: Nifurtimox (BAYa2502) (120 mg tablet)
5 Completed
Has Results
A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy
Condition: Moderate to Severe Pain Due to Diabetic Polyneuropathy
Interventions: Drug: Oxycodone Naloxone;   Drug: Placebo tablets
6 Recruiting Radiomic Assessment in NSCLC: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
Condition: Lung Cancer
Intervention:
7 Completed
Has Results
Irinotecan Study For Cervical Cancer
Condition: Uterine Cervical Neoplasms
Intervention: Drug: Irinotecan
8 Completed Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: COLAL-PRED®;   Drug: Prednisolone
9 Completed Can Structured Education Promote Physical Activity in Those Identified With an Increased Risk of Developing Diabetes
Condition: Prediabetic State
Interventions: Behavioral: PREPARE with pedometer;   Behavioral: PREPARE
10 Completed NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)
Condition: Head and Neck Neoplasms
Intervention: Drug: DOCETAXEL(XRP6976)
11 Completed GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer
Condition: Breast Neoplasms
Intervention: Drug: DOCETAXEL
12 Completed TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian
Condition: Ovarian Neoplasms
Intervention: Drug: Docetaxel
13 Unknown  Methods of Improvement Adherence With Therapy in Ulcerative Colitis.
Condition: Ulcerative Colitis
Intervention: Behavioral: Range of electronic pill dispensers with alarms
14 Completed
Has Results
Natural Orifice Transgastric Endoscopic (NOTES) Transgastric Diagnostic Peritoneoscopy With Laparoscopic Assistance
Condition: Abdominal Adhesions
Intervention: Device: Transgastric diagnostic peritoneoscopy with laparoscopic assistance
15 Recruiting Benfotiamine in Alzheimer's Disease: A Pilot Study
Condition: Alzheimer's Disease
Intervention: Drug: Benfotiamine
16 Completed Detection of Pulmonary Embolism With Low-dose CT Pulmonary Angiography
Condition: Embolism, Pulmonary
Intervention: Radiation: Computed tomography pulmonary angiography
17 Recruiting Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
Conditions: Axial Spondyloarthrithis;   Ankylosing Spondylitis
Interventions: Biological: Certolizumab Pegol;   Other: Placebo
18 Recruiting Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: ponesimod;   Drug: teriflunomide
19 Active, not recruiting Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Ponesimod 10 mg;   Drug: Ponesimod 20 mg;   Drug: Ponesimod 40 mg
20 Completed ACT-128800 in Relapsing-remitting Multiple Sclerosis
Condition: Relapsing-remitting Multiple Sclerosis
Interventions: Drug: ACT-128800;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.